Amsterdam Spondyloarthritis cohort (AmSpA cohort)

Phase 4

Conditions: Spondyloarthritis
10023213

Registration Number: NL-OMON47286

Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 1000

Inclusion Criteria

-* diagnosis of axial or peripheral spondyloarthritis, according to the:
o the modified New York criteria OR
o the ESSG criteria OR
o the ASAS classification criteria, including axial as well as peripheral SpA
* signed informed consent

Exclusion Criteria

Unable to understand the study aims and methods;Remark: For patients initiating a biological, a treatment selection in daily clinical practice on contra-indications described in the Dutch national guidelines for initiation of a biological treatment, were taken into consideration, especially considering females. An exception is made for treatment with certoluzimab, which can be continued during late gestation and during breastfeeding

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Parameters that were collected during the regular visits at the outpatient<br /><br>clinic are: (changes in) disease activity (BASDAI and ASDAS and inflammatory<br /><br>markers (CRP- and ESR-levels), frequency of adverse events and drug adherence<br /><br>and response during biological treatment and disease progression (radiographic<br /><br>changes on X-rays and /or MRI, and change of classification from nr-axial SpA<br /><br>to AS). In addition, parameters concerning changes in function (BASFI), in<br /><br>range of motion (BASMI), occurrence of extra-articular manifestations and<br /><br>comorbidities and BMD change (DEXA scans) were collected during the regular<br /><br>visits. </p><br>

Secondary Outcome Measures